Susquehanna International Group
RXRX icon

Susquehanna International Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Susquehanna International Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.08M Buy
2,632,200
+424,500
+19% +$1.64M ﹤0.01% 3448
2025
Q4 		$9.03M Buy
2,207,700
+173,500
+9% +$859K ﹤0.01% 3186
2025
Q3 		$9.93M Sell
2,034,200
-335,500
-14% -$1.76M ﹤0.01% 3048
2025
Q2 		$12M Buy
2,369,700
+946,600
+67% +$4.65M ﹤0.01% 2602
2025
Q1 		$7.53M Buy
1,423,100
+431,200
+43% +$3.14M ﹤0.01% 2918
2024
Q4 		$6.71M Buy
991,900
+400,400
+68% +$2.69M ﹤0.01% 3166
2024
Q3 		$3.9M Buy
591,500
+288,000
+95% +$2.06M ﹤0.01% 4051
2024
Q2 		$2.28M Sell
303,500
-19,100
-6% -$167K ﹤0.01% 4847
2024
Q1 		$3.22M Buy
322,600
+24,800
+8% +$276K ﹤0.01% 4380
2023
Q4 		$2.94M Buy
297,800
+76,200
+34% +$543K ﹤0.01% 4613
2023
Q3 		$1.7M Buy
221,600
+150,900
+213% +$1.51M ﹤0.01% 5472
2023
Q2 		$528K Buy
70,700
+27,700
+64% +$194K ﹤0.01% 8184
2023
Q1 		$287K Buy
43,000
+32,900
+326% +$261K ﹤0.01% 9824
2022
Q4 		$77.9K Sell
10,100
-53,200
-84% -$522K ﹤0.01% 11147
2022
Q3 		$674K Buy
63,300
+36,600
+137% +$371K ﹤0.01% 7674
2022
Q2 		$217K Buy
+26,700
New +$179K ﹤0.01% 10441
2021
Q4 		– Sell
-16,700
Closed -$384K – 13799
2021
Q3 		$384K Buy
+16,700
New +$473K ﹤0.01% 10029

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's RXRX Position: Q1 2026 in Review

Susquehanna International Group reduced its Recursion Pharmaceuticals (RXRX) stake by 3.9% in Q1 2026, selling an estimated $660K and leaving 4,225,277 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #2740.

Susquehanna International Group first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $26.3M in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Susquehanna International Group held 4,225,277 shares of Recursion Pharmaceuticals worth $13M as of Q1 2026.
  • Susquehanna International Group sold 170,827 Recursion Pharmaceuticals shares in Q1 2026, an estimated $660K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2740 holding.
  • Susquehanna International Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Susquehanna International Group's Recursion Pharmaceuticals position peaked at $26.3M in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.